Abstract
The pharmaceutical industry is no longer the “analysts’ darling” — quite the reverse is true. The industry is currently facing increasing pressure due to the lack of innovateon and productivity in drug research and development (Fig. 1, global R&D productivity trend 1991–2001).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493–502
Cohen P (2002) Protein kinases — the major drug targets of the twenty-first century? Nat Rev Drug Discov 1: 309–315
Kornberg A (1987) The two cultures: chemistry and biology. Biochemistry 26: 6888–6891
Schreiber S, Nicolaou K C (1996) The best is yet to come. Chem Biol 3:1–2 Wess G (2002) How to escape the bottleneck of medicinal chemistry. DDT 7: 533–535
Wess G, Urmann M, Sickenberger B (2001) Medicinal chemistry: challenges and opportunities. Angew. Chem Int Ed 40: 3341–3350
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Reinhard-Rupp, J., Wess, G. (2003). Drug Discovery Opportunities. In: Waldmann, H., Koppitz, M. (eds) Small Molecule — Protein Interactions. Ernst Schering Research Foundation Workshop, vol 42. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-05314-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-662-05314-0_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-05316-4
Online ISBN: 978-3-662-05314-0
eBook Packages: Springer Book Archive